YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
A phase 3 trial testing YL202 in HR-positive / HER2-negative breast cancer, now recruiting.
Overview
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT07461454, led by MediLink Therapeutics (Suzhou), and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 376 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Shares YL202, MediLink Therapeutics and the tag ctgov-ingest.
- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialPhase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.